Out of public view, corporations are cutting deals that give consumers little choice but to buy brand-name drugs—and sometimes pay more at the pharmacy counter than they would for generics.
The pharmaceutical world is rife with rebates and side deals—all designed to elbow ahead of the competition. But apparently the price of convenience comes at a steep mark-up.